Last reviewed · How we verify
Combizym
Combizym, marketed by RenJi Hospital, is a drug with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but its key strength lies in its current marketed status, providing a stable revenue stream. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Combizym |
|---|---|
| Also known as | Oryz-Aspergillus Enzyme And Pancreatin Tablet, (provided by Nordmark Arzneimittel GmbH & Co. KG) |
| Sponsor | RenJi Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Clinical Study on Combizym and Bifidobacteri to Prevent the Recurrence of Colon Polyps (PHASE4)
- A Study of Oryz-Aspergillus Enzyme and Pancreatin Tablet in Patients With Cirrhosis and Malnutrition (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Combizym CI brief — competitive landscape report
- Combizym updates RSS · CI watch RSS
- RenJi Hospital portfolio CI